New assay to predict patient response to immunotherapy
2018
Johns Hopkins University School of Medicine, Baltimore, USA
Patients can mount endogenous immune responses against mutation-associated neoantigens (MANA), but these responses are countered by immunosuppressive signals—so-called checkpoints. Unleashing of MANA-specific T cells by checkpoint blockade promotes tumor regression in patients. In the present study, the researchers develop an assay called MANAFEST to identify MANA-specific immune response in tumor tissue and in the blood by checkpoint blockade. This assay has great sensitivity, specificity and high-throughput capacity and could be used as a pan-cancer predictor of response to immunotherapy.
The mutation-associated neoantigen functional expansion of specific T cells (MANAFEST) assay: a sensitive platform for monitoring antitumor immunity
Kellie N. Smith
Added on: 07-26-2021
[1] https://cancerimmunolres.aacrjournals.org/content/6/8/888[2] https://data.jrc.ec.europa.eu/dataset/352f7dfd-05cf-434b-a96a-7e270dc76573
